Pages that link to "Q57004880"

The following pages link to Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response (Q57004880):

Displaying 26 items.

• Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. (Q33819124) (← links)
• The Role of Interferon in Hepatitis B Therapy (Q34154958) (← links)
• Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. (Q34594403) (← links)
• Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses (Q35023484) (← links)
• AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B. (Q35866293) (← links)
• Treatment of chronic hepatitis B infection: an update of Swedish recommendations (Q37201573) (← links)
• Endpoints of therapy in chronic hepatitis B. (Q37462552) (← links)
• Predictors of treatment response in chronic hepatitis B. (Q37620332) (← links)
• Different Mechanisms May Exist for HBsAg Synthesis and Secretion During Various Phases of Chronic Hepatitis B Virus Infection (Q37726148) (← links)
• Review article: chronic hepatitis B – anti‐viral or immunomodulatory therapy? (Q37825532) (← links)
• HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients (Q38295840) (← links)
• Predictive model for inflammation grades of chronic hepatitis B: Large-scale analysis of clinical parameters and gene expressions. (Q40281137) (← links)
• Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α. (Q40557516) (← links)
• Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta (Q42234354) (← links)
• Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study (Q42271417) (← links)
• Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. (Q42590869) (← links)
• Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline (Q42911213) (← links)
• Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels (Q42947260) (← links)
• Two Patterns of Alanine Aminotransferase Increase to Predict Long-Term Viral Response in Chronic Hepatitis B Patients: Virus- or Host-Induced? (Q43036624) (← links)
• Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels (Q44408807) (← links)
• Characterization of microRNA expression profiles associated with hepatitis B virus replication and clearance in vivo and in vitro (Q44824138) (← links)
• HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo (Q45166709) (← links)
• Interferon in hepatitis B (Q46188063) (← links)
• Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. (Q52632461) (← links)
• Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes (Q59352172) (← links)
• Elevated serum levels of soluble CD14 in HBeAg-positive chronic HBV patients upon Peginterferon treatment are associated with treatment response (Q92030881) (← links)